Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
H.C.
Ram Selvaraju needs to see more proof of VRX’s pipeline staying power and ability to yield gains.
OTIC stock fired to the roof after successful late-trial results in Meniere’s; Edward Nash cheers.
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S.
Omeros Corporation (NASDAQ:OMER) shares are on fire this evening, rising nearly 11%, after the drug maker reported better-than-expected 3Q Omidria sales. Third Quarter Highlights 3Q …
BTIG’s Tim Chiang believes a lot hinges on the Vyzulta launch for VRX to stage a solid comeback.
Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.
KERX pulled Auryxia guidance for the year after a rocky third quarter performance; Cowen’s Boris Peaker thumbs down.
